In stroke patients, peripheral blood ADAM17 activity and soluble CD163 levels are elevated, whereby CD163 can be shed from the plasma membrane via the metalloprotease ADAM17 to generate a soluble peptide with lympho-inhibitory properties [43]. The gene discussed is ADAM17; the disease is Stroke.